Humacyte, Inc. (HUMA) DCF Valuation

Humacyte, Inc. (HUMA) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Humacyte, Inc. (HUMA) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Humacyte, Inc.? Our HUMA DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and make more informed investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 6.2 1.5 1.3 1.6 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -75.9 -15.29 23.91 -100 -41.82 -41.82 -41.82 -41.82 -41.82
EBITDA -78.9 -56.2 -73.0 2.5 -96.5 .0 .0 .0 .0 .0
EBITDA, % -1275.93 -3772.57 -5777.28 159.11 100 -20 -20 -20 -20 -20
Depreciation 6.7 8.4 8.3 8.3 7.7 .0 .0 .0 .0 .0
Depreciation, % 109.08 565.53 655.82 527.48 100 100 100 100 100 100
EBIT -85.7 -64.7 -81.2 -5.8 -104.2 .0 .0 .0 .0 .0
EBIT, % -1385.02 -4338.1 -6433.1 -368.37 100 -60 -60 -60 -60 -60
Total Cash 93.7 39.9 225.5 151.9 80.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .6 .1 .2 .0 .0
Account Receivables, % 9.71 7.58 13.94 1.98 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0.000016162922 0.000067069081 0.000079176564 -1.98 100 19.6 19.6 19.6 19.6 19.6
Accounts Payable 3.3 2.3 2.1 1.6 6.5 .0 .0 .0 .0 .0
Accounts Payable, % 52.89 152.52 165.8 101.92 100 90.58 90.58 90.58 90.58 90.58
Capital Expenditure -8.1 -.3 -.2 -1.0 -2.3 .0 .0 .0 .0 .0
Capital Expenditure, % -131.32 -21.33 -17.42 -66.96 100 -41.14 -41.14 -41.14 -41.14 -41.14
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -85.7 -66.8 115.2 30.9 -104.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -84.4 -59.2 123.0 37.8 -93.8 -6.5 .0 .0 .0 .0
WACC, % 10.73 10.73 10.32 10.32 10.73 10.56 10.56 10.56 10.56 10.56
PV UFCF
SUM PV UFCF -5.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -6
Net Debt -22
Equity Value 17
Diluted Shares Outstanding, MM 103
Equity Value Per Share 0.16

What You Will Get

  • Pre-Filled Financial Model: Humacyte’s actual data enables precise DCF valuation.
  • Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
  • Instant Calculations: Automatic updates ensure you see results as you make changes.
  • Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
  • Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.

Key Features

  • 🔍 Real-Life HUMA Financials: Pre-filled historical and projected data for Humacyte, Inc. (HUMA).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Humacyte’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Humacyte’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based HUMA DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
  3. Instant Calculations: The model automatically recalculates Humacyte’s intrinsic value.
  4. Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
  5. Analyze and Decide: Utilize the outcomes to inform your investment or financial strategies.

Why Choose This Calculator for Humacyte, Inc. (HUMA)?

  • Accurate Data: Up-to-date Humacyte financials provide trustworthy valuation outcomes.
  • Customizable: Tailor essential variables like growth rates, WACC, and tax rates to suit your forecasts.
  • Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Simple design and clear instructions make it accessible for all users.

Who Should Use This Product?

  • Investors: Accurately assess Humacyte's fair value before making investment decisions.
  • CFOs: Utilize a professional-grade DCF model for financial reporting and analysis.
  • Consultants: Easily customize the template for valuation reports tailored to clients.
  • Entrepreneurs: Acquire insights into financial modeling practices used by leading biotech firms.
  • Educators: Employ it as a teaching resource to illustrate valuation methodologies.

What the Template Contains

  • Historical Data: Includes Humacyte’s past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Humacyte’s intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Humacyte’s financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.